Needham Maintains Buy on OncoCyte, Lowers Price Target to $4.25
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has maintained a 'Buy' rating on OncoCyte (NASDAQ:OCX), but lowered the price target from $9 to $4.25.
August 10, 2023 | 3:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst has maintained a 'Buy' rating on OncoCyte but lowered the price target from $9 to $4.25.
The news is directly related to OncoCyte (OCX). The maintained 'Buy' rating indicates a positive outlook for the company, however, the lowered price target may indicate a potential downside, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100